



Form PTO 1449 (Modified)  LIST OF REFERENCES CITED BY APPLICANT NOV 28 2006		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 285327US0PCT	SERIAL NO. 10/566,253		
		APPLICANT		Yukihiko SAEKI, et al.			
		FILING DATE		January 30, 2006			
							GROUP 1615
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	AN						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
C2	AO	Kikuo ISODA, et al., "Osteopontin Plays an Important Role in the Development of Medial Thickening and Neointimal Formation", Circulation Research, JOURNAL OF THE AMERICAN HEART ASSOCIATION, http://www.circresaha.org , 91, 1, July 12, 2002, pages 77-82					
1	AP	Stefan GAUER, et al., "Differential Regulation of Osteopontin Expression in the Clipped and Nonclipped Kidney of Two-Kidney, One-Clip Hypertensive Rats", American Journal of Hypertension, Ltd., vol. 16, no. 3, March 2003, pages 214-222					
	AQ	Yoshinobu KOGUCHI, et al., "High Plasma Osteopontin Level and Its Relationship with Interleukin-12-mediated Type 1 T Helper Cell Response in Tuberculosis", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 167, no. 10, May 15, 2003, pages 1355-1359					
	AR	Kayo MAEDA, et al., "Distinct Roles of Osteopontin Fragments in the Development of the Pulmonary Involvement in Sarcoidosis", Lung, vol. 179, no. 5, 2002, pages 279-291					
	AS	Rumiko KAWASHIMA, et al., "Expression of Osteopontin in Kupffer Cells and Hepatic Macrophages and Stellate Cells in Rat Liver after Carbon Tetrachloride Intoxication: A Possible Factor for Macrophage Migration into Hepatic Necrotic Areas", Biochemical and Biophysical Research Communications, vol. 256, no. 3, 1999, pages 527-531					
	AT	Deepak AGRAWAL, et al., "Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling", Journal of the National Cancer Institute, vol. 94, no. 7, April 3, 2002, pages 513-521					
	AU	Jae-Hoon KIM, MD, et al., "Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer", JAMA, www.jama.com , vol. 287, no. 13, April 3, 2002, pages 1671-1679					
	AV	George N. THALMANN, et al., "Osteopontin: Possible Role in Prostate Cancer Progression", Clinical Cancer Research, vol. 5, no. 8, August 1999, pages 2271-2277					
	AW	Hemant SINGHAL, et al., "Elevated Plasma Osteopontin in Metastatic Breast Cancer Associated with Increased Tumor Burden and Decreased Survival", Clinical Cancer Research, vol. 3, April 1997, pages 605-611					
	AX	Kenjiro KOHRI, et al., "Structure and Expression of the mRNA Encoding Urinary Stone Protein (Osteopontin)", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 20, July 15, 1993, pages 15180-15184					
CH	AY	Yuko OYAMA, et al., "PPAR γ Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells", Circulation Research, http://www.circresaha.org , 90, February 22, 2002, pages 348-355					
CH	AZ	Minoru TAKEMOTO, et al., "NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells", British Journal of Pharmacology, vol. 133, 2001, pages 83-88					
						<input type="checkbox"/> Additional References sheet(s) attached	
Examiner 				Date Considered 8/27/07			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 285327US0PCT	SERIAL NO. 107566253 VIEW U.S. Application Based on PCT/JP04/10810
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Yukihiko SAEKI, et al.	
		FILING DATE Herewith	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
<i>Cn</i>	AO	2001-526263	12/18/01	JP (equivalent of WO99/32448)		NO
<i>Cn</i>	AP	99/25697	05/27/99	WO (English abstract only & equivalent of US6,348,468)		NO
<i>Cn</i>	AQ	2001-522834	11/20/01	JP (English abstract only & equivalent of WO 99/24404)		NO
<i>Cn</i>	AR	2001-521934	11/13/01	JP (English abstract only & equivalent of WO99/23091)		NO
<i>V</i>	AS	2003-63966	03/05/03	JP (English abstract only)		NO
<i>Cn</i>	AT	2002-511887	04/16/02	JP (English abstract only & equivalent of WO99/10332)		NO
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

<i>Cn</i>	AW	NICOLA, G. et al., Osteopontin Is Produced by Human Multiple Myeloma Cells, Blood, Vol. 100, No. 11, Pages 378b, 2002.
<i>Cn</i>	AX	MATSUDA, Takayuki et al., Synthesis and Bioactivities of Novel 5, 6-Bis (4-methoxyphenyl) - 2H-pyridazin-3-one Derivatives: Inhibitors of Interleukin-1 Beta (IL-1 β) Production, Bioorganic & Medicinal Chemistry Letters, Vol. 11, No. 17, Pages 2373 to 2375, 2001
	AY	
	AZ	
Examiner		<input type="checkbox"/> Additional References sheet(s) attached
		Date Considered <i>8/27/07</i>

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.